Sharekhan

Alivus Life Sciences Ltd

Mon 3/11/2025,15:44:16 NSE: ALIVUS

₹ 918.05 13.60 (1.50%)
BUY NOW Buy Alivus Life Sciences Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Alivus Life Sciences Ltd

Mon 3/11/2025,16:1:0

Alivus Life Sciences Ltd

Mon 3/11/2025,15:44:16 | NSE : ALIVUS

₹ 918.0513.60 (1.50%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 911.55

Previous Close

₹ 904.45

Volume

77191

Mkt Cap ( Rs. Cr)

₹11262.76

High

₹ 933.00

Low

₹ 904.45

52 Week High

₹ 1251.00

52 Week Low

₹ 850.00

Book Value Per Share

₹ 229.65

Dividend Yield

0.00

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on Alivus Life Sciences Ltd

Your Vote -

Buy

90.78%

Hold

7.28%

Sell

1.94%

90.78%

206 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

918.05

155

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

155

Option Chain

Analyzes market sentiment, predicts Alivus Life Sciences Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    30 Oct 2025, 3:46PM Enclosed please find herewith the details of Earnings Call slated for Friday, November 7, 2025 from 8:30 a.m. to 9:30 a.m. (IST), for your information

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    30 Oct 2025, 3:39PM Alivus Life Sciences Limited has informed the Exchange about Schedule of meet

  • Alivus Life Sciences - Trading Window

    29 Oct 2025, 5:44PM Alivus Life Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulati

  • Alivus Life Sciences - Board Meeting Intimation for Unaudited Financial Results Of The Company For The Quarter And Half Year

    29 Oct 2025, 5:36PM Alivus Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2025 ,inter alia, to consider

  • Alivus Life Sciences - Disclosure under Regulation 30 of LODR

    20 Oct 2025, 9:46AM Alivus Life Sciences Ltd has informed BSE regarding the details of Notice/Order received by the Company from Office of The Gujarat Pollution Control B

  • Alivus Life Sciences - General Updates

    19 Oct 2025, 10:17AM Alivus Life Sciences Limited has informed the Exchange about General Updates

  • Alivus Life Sciences has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2025

    11 Oct 2025, 7:03AM As of September 2025, 74.91% is owned by Indian Promoters and 25.09% by Public. <p align=justify> Institutional holds 12.31% (Insurance Companies 0.24

  • Alivus Life Sciences - General Updates

    2 Oct 2025, 11:52AM Alivus Life Sciences Limited has informed the Exchange about General Updates

  • Alivus Life Sciences - Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And

    2 Oct 2025, 11:46AM Disclosure under Regulation 30 of SEBI LODR

  • Alivus Life Sciences - Credit Rating- Revision

    16 Sep 2025, 3:45PM Alivus Life Sciences Limited has informed the Exchange about Credit Rating- Revision

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Credit Rating

    16 Sep 2025, 3:38PM India Rating upgrades Alivus Life Sciences's Bank loan facilities to 'IND AA' ; Outlook stable.

  • Alivus Life Sciences - General Updates

    8 Sep 2025, 8:47PM Alivus Life Sciences Limited has informed the Exchange about Appointment of Secretarial Auditor

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Change in Management

    8 Sep 2025, 8:47PM Please find attached herewith intimation with respect to Appointment of Secretarial Auditor.

  • Alivus Life Sciences - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    8 Sep 2025, 8:42PM Please find attached herewith Scrutinizers Report.

  • Alivus Life Sciences - Shareholders meeting

    8 Sep 2025, 8:36PM Alivus Life Sciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 08, 2025. Further, the compan

  • Alivus Life Sciences - Shareholder Meeting / Postal Ballot-Outcome of AGM

    8 Sep 2025, 8:36PM Proceedings of the 14th Annual General Meeting (AGM) of Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) held on 08th September,

  • Alivus Life Sciences - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    8 Sep 2025, 8:42PM Please find attached herewith Scrutinizers Report.

  • Alivus Life Sciences - Address Change

    3 Sep 2025, 5:49PM Alivus Life Sciences Limited has informed the Exchange regarding change in Corporate Office of the company.

  • Alivus Life Sciences - Change In Corporate Office Address.

    3 Sep 2025, 5:45PM Change in Corporate Office address.

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    26 Aug 2025, 11:39AM Alivus Life Sciences Limited has informed the Exchange about Schedule of meet

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    26 Aug 2025, 11:35AM Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    21 Aug 2025, 3:22PM Alivus Life Sciences Limited has informed the Exchange about Schedule of meet

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    21 Aug 2025, 3:17PM Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting

  • Alivus Life Sciences - General Updates

    20 Aug 2025, 2:25PM Alivus Life Sciences Limited has informed the Exchange about General Updates

  • Alivus Life Sciences - Disclosure under Regulation 30A of LODR

    20 Aug 2025, 2:21PM Disclosure under Regulation 30A of LODR

  • Alivus Life Sciences - Copy of Newspaper Publication

    15 Aug 2025, 5:07PM Alivus Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication

  • Alivus Life Sciences - General Updates

    12 Aug 2025, 4:14PM Alivus Life Sciences Limited has informed the Exchange about Business Responsibility & Sustainability Report for FY 2024-25

  • Alivus Life Sciences - Shareholders meeting

    12 Aug 2025, 3:57PM Alivus Life Sciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 08, 2025

  • Alivus Life Sciences - Copy of Newspaper Publication

    12 Aug 2025, 3:28PM Alivus Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication

  • Alivus Life Sciences - Business Responsibility & Sustainability Report For FY 2024-25

    12 Aug 2025, 4:19PM Business Responsibility & Sustainability Report for FY 2024-25

  • Alivus Life Sciences - Reg. 34 (1) Annual Report.

    12 Aug 2025, 3:51PM Submission of Integrated Annual Report under Regulation 34 (1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

  • Alivus Life Sciences - Notice Of 14Th Annual General Meeting Of The Company For FY 2024-25 As Required Under Regulation 30 Of

    12 Aug 2025, 3:42PM Notice of 14th Annual General Meeting

  • Alivus Life Sciences has declared 250% Final dividend for the financial year March 2025

    12 Aug 2025, 12:11PM Alivus Life Sciences Ltd. on Thursday, 15 May 2025, has announced Final dividend of 250 percent on Equity Share, to its shareholders holding shares on

  • Alivus Life Sciences - Record Date

    11 Aug 2025, 11:09AM Alivus Life Sciences Limited has informed the Exchange that Record date for the purpose of Dividend is 01-Sep-2025.

  • Alivus Life Sciences - Shareholders meeting

    11 Aug 2025, 11:06AM Alivus Life Sciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 08, 2025

  • Alivus Life Sciences - Intimation Of Record Date For Dividend

    11 Aug 2025, 11:01AM Intimation of Record Date for Dividend

  • Alivus Life Sciences - Intimation Of 14Th Annual General Meeting And Record Date

    11 Aug 2025, 10:58AM Intimation of 14th Annual general Meeting and Record date

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    8 Aug 2025, 5:00PM Alivus Life Sciences Limited has informed the Exchange about Transcript

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    8 Aug 2025, 4:55PM Enclosed please find Transcript of Earnings Call

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    4 Aug 2025, 5:54PM Alivus Life Sciences Limited has informed the Exchange about Schedule of meet

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    4 Aug 2025, 5:50PM Please find attached herewith Analyst/ Investors Meet.

  • Glenmark Life Science

    11 Jul 2024 , 10:12AM Glenmark Pharmaceuticals' board of directors approved the sale of a 7.84% stake or 96,09,571 equity shares, in Glenmark Life Sciences Limited, as stated in its filing to the exchanges on Wednesday. The stake sale will be done through the stock exchanges via an offer for sale. (Negative)

  • Glenmark Life signs master supply agreement with a Japanese innovator pharma co

    19 Jan 2024 , 11:07AM Glenmark Life Sciences signs Master Supply Agreement with a leading Japanese Innovator pharmaceutical Company

  • Glenmark Lifesciences

    31 Jul 2023 , 10:32AM The Nirma Group has emerged as the frontrunner to acquire Glenmark Life Sciences (GLS), an 82.84% subsidiary of Glenmark Pharmaceuticals. Strong positive for Glenmark Lifesciences

  • Glenmark Life Sciences report strong Q1 earnings

    21 Jul 2023 , 1:38PM Glenmark Life Sciences reported an 18% y-o-y rise in revenue to Rs 578.45 Cr in Q1FY24. It was driven by a 13.3% y-o-y increase in Generic API revenue to Rs. 504.2 Cr due to strong growth in regulated markets and steady growth in emerging markets while CDMO business recorded 91.0% growth y-o-y to Rs. 46.4 Cr due to healthy recovery in demand. As gross margins improved 385 bps y-o-y to 57% the gross profits increased 27% y-o-y to Rs. 330.41 Cr. This was driven by lower input costs and improved products mix. As a result, EBITDA increased 32% y-o-y to Rs. 193.16 Cr. while EBITDA margins remained stable y-o-y at 33% in Q1FY24. However, with 193% y-o-y rise in finance costs to Rs. 0.40 Cr the PAT increased at a slower but strong pace of 25% y-o-y to Rs. 135.45 Cr in Q1FY24. However, on a q-o-q basis, revenue and PAT declined at 7% each. Sales declined q-o-q due to high base effect. The management is hopeful of growth in the coming quarters on the back of capacity expansion and product pipeline as well as improved demand environment and supply situation. Positive for the stock.
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Alivus Life Sciences Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 2817.372 2332.322 2138.207 2054.312 752.747
Liabilities 2817.372 2332.322 2138.207 2054.312 752.747
Equity 24.507 24.505 24.505 24.505 1.96
Gross Profit 682.584 674.246 642.293 616.06 591.074
Net Profit 485.627 470.888 466.961 418.724 351.581
Cash From Operating Activities 391.524 413.515 313.404 597.585 388.113
NPM(%) 20.34 20.62 21.6 19.72 18.64
Revenue 2386.884 2283.214 2161.22 2123.214 1885.165
Expenses 1704.3 1608.968 1518.927 1507.154 1294.091
ROE(%) 17.23 16.71 16.57 14.86 12.47

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
01 Sep 2025 5 250 0 1206
17 Oct 2023 22.5 1125 0 617.7
24 Mar 2023 21 1050 0 375.3
15 Sep 2022 10.5 525 0 489
22 Nov 2021 10.5 525 0 632.7

Peers

Other companies within the same industry or sector that are comparable to Alivus Life Sciences Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 883.05 3.90 80.06 516.93 301.39 0.57
Lotus Eye Hospital and Institute Ltd 131.17 4.91 423.13 1883.62 3.55 0.00
Vaishali Pharma Ltd 10.00 -0.40 333.33 11816.61 3.13 0.00
Astec Lifesciences Ltd 672.25 1.85 0.00 1776.30 -604.77 0.00

Company Info

The Company was incorporated as `Zorg Laboratories Private Limited', a private limited company under the Companies Act, 1956 on June 23, 2011 at Pune and was granted the certificate of incorporation by the RoC. the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated July 4, 2018. For further details, please see - "Details regarding material acquisitions or divestments of business/ undertakings, mergers, amalgamations or any revaluation of assets, in the last 10 years - Acquisition by Glenmark Pharmaceuticals Limited" on page 151. Pursuant to the acquisition, the name of the Company was changed to `Glenmark Life Sciences Private Limited' by way of a special resolution passed by the shareholders of the Company on July 25, 2018 and a fresh certificate of incorporation dated August 10, 2018 was issued by the RoC. A shareholders' resolution was passed on August 13, 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated August 28, 2018 was issued by the RoC. Thereafter, the business of active pharmaceutical ingredients was acquired by the Company from the Promoter pursuant to the Business Purchase Agreement.Major events and milestones of the Company :2002- The Promoter established its API business- Established manufacturing plant at Kurkumbh, Maharashtra2003- First product registered with US-FDA- Acquired GlaxoSmithKline's (GSK) API manufacturing plant in Ankleshwar, Gujarat2004- Commenced manufacturing at Mohol, Maharashtra2008- Ankleshwar plant at Gujarat inspected by US-FDA2012- Ankleshwar plant inspected by PMDA and AFSSAPS2013- Commenced manufacturing at Dahej, Gujarat- Ankleshwar plant inspected by COFEPRIS2015- Dahej plant inspected by US-FDA2016- Dahej plant inspected by PMDA Japan2018- Dahej plant inspected by EDQM, ANSM and US-FDA- Mohol plant inspected by US-FDA2019- The API business was spun off into the Company- Ankleshwar plant inspected by US-FDA, Health Canada and PMDA, Japan2021- Achieved milestone of 403 cumulative drug master files (DMF) registrations across multiple markets globally 2023 -The Company had announced that its board had given the green light to divest a 75% stake in its subsidiary GLS to Nirma Ltd for a total of Rs 5,651.5 crore.

The Company was incorporated as `Zorg Laboratories Private Limited', a private limited company under the Companies Act, 1956 on June 23, 2011 at Pune and was granted the certificate of incorporation by the RoC. the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated July 4, 2018. For further details, please see - "Details regarding material acquisitions or divestments of business/ undertakings, mergers, amalgamations or any revaluation of assets, in the last 10 years - Acquisition by Glenmark Pharmaceuticals Limited" on page 151. Pursuant to the acquisition, the name of the Company was changed to `Glenmark Life Sciences Private Limited' by way of a special resolution passed by the shareholders of the Company on July 25, 2018 and a fresh certificate of incorporation dated August 10, 2018 was issued by the RoC. A shareholders' resolution was passed on August 13, 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated August 28, 2018 was issued by the RoC. Thereafter, the business of active pharmaceutical ingredients was acquired by the Company from the Promoter pursuant to the Business Purchase Agreement.Major events and milestones of the Company :2002- The Promoter established its API business- Established manufacturing plant at Kurkumbh, Maharashtra2003- First product registered with US-FDA- Acquired GlaxoSmithKline's (GSK) API manufacturing plant in Ankleshwar, Gujarat2004- Commenced manufacturing at Mohol, Maharashtra2008- Ankleshwar plant at Gujarat inspected by US-FDA2012- Ankleshwar plant inspected by PMDA and AFSSAPS2013- Commenced manufacturing at Dahej, Gujarat- Ankleshwar plant inspected by COFEPRIS2015- Dahej plant inspected by US-FDA2016- Dahej plant inspected by PMDA Japan2018- Dahej plant inspected by EDQM, ANSM and US-FDA- Mohol plant inspected by US-FDA2019- The API business was spun off into the Company- Ankleshwar plant inspected by US-FDA, Health Canada and PMDA, Japan2021- Achieved milestone of 403 cumulative drug master files (DMF) registrations across multiple markets globally 2023 -The Company had announced that its board had given the green light to divest a 75% stake in its subsidiary GLS to Nirma Ltd for a total of Rs 5,651.5 crore.

Read More

Parent Organisation

Alivus Life Sciences Ltd.

Founded

23/06/2011

Managing Director

Dr.Yasir Rawjee

NSE Symbol

ALIVUSEQ

FAQ

The current price of Alivus Life Sciences Ltd is ₹ 918.05.

The 52-week high for Alivus Life Sciences Ltd is ₹ 933.00 and the 52-week low is ₹ 904.45.

The market capitalization of Alivus Life Sciences Ltd is currently ₹ 11262.76. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Alivus Life Sciences Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Alivus Life Sciences Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Alivus Life Sciences Ltd shares.

The CEO of Alivus Life Sciences Ltd is Dr.Yasir Rawjee, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT